AstraZeneca's breast cancer drug Etcamah failed to meet its primary goal of improving progression-free survival in the Phase III SERENA-4 trial, as announced by the company. According to Rediff Moneynews, the Etcamah-palbociclib combination did not show statistically significant improvement in progression-free survival versus Ibrance plus the aromatase inhibitor Arimidex (anastrozole) with palbociclib, despite a numerical improvement being observed in first-line treatment. The drug did not achieve the main endpoint of the study, representing a significant setback for the recently approved treatment. The SERENA-4 trial enrolled approximately 1,371 individuals with previously untreated advanced hormone receptor-positive, HER2-negative breast cancer and showed that the Etcamah-palbociclib combination was compared against Ibrance and treatments that lower hormones fuelling the cancer, with the trial involving 1,371 patients with the most common type of advanced breast cancer where hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Camizestrant is a targeted breast cancer medicine designed to block the activity of the oestrogen receptor and belongs to a class of drugs called selective oestrogen receptor degraders (SERDs).
US-listed shares of AstraZeneca dropped about 3 per cent in aftermarket trading following the news of the trial failure, as reported by Investing.com, The Economic Times, ETPharma, and TradingView News. The market reaction reflects investor concerns about the drug's clinical effectiveness and potential impact on future treatment options for advanced breast cancer patients. However, analysts are taking a more measured view of the results. RBC Capital analyst Trung Huynh described the outcome as a 'manageable setback' that largely clears short-term uncertainty for investors, without fundamentally changing the long-term investment case for Etcamah. Barclays analyst James Gordon called the update 'well anticipated by the market', given the previous failure of Roche's similar drug combination in March and AstraZeneca's cautious trial commentary.
Regarding the drug's safety, AstraZeneca noted that the safety profile of Etcamah in combination with palbociclib was consistent with the known profiles of each medicine, with no new safety concerns identified. According to Rediff Moneynews, Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, stated that 'whilst we are disappointed by the SERENA-4 outcome, it sharpens our focus on maximising the number of patients who can benefit from Etcamah today based on SERENA-6 and reinforces the importance of ESR1 testing for patients on first-line therapy'. Galbraith added that early breast cancer represents an important opportunity, and the company remains confident in the long-term potential of the drug. The trial results mark an early challenge for Etcamah, which just last week received accelerated approval from the U.S. Food and Drug Administration to be used together with certain targeted cancer medicines known as CDK4/6 inhibitors. The full trial data will be shared at an upcoming medical meeting, providing additional information about the clinical trial results and their implications for the drug's development program.
Despite the SERENA-4 trial failure, Etcamah remains in two other phase 3 trials, CAMBRIA-1 and CAMBRIA-2, that have enrolled about 10,000 patients examining the drug in individuals with intermediate and high risk of recurrence in the adjuvant setting as monotherapy, in combination with CDK4/6 inhibitors, and following CDK4/6 inhibitor treatment. As reported by TradingView News, these trials will continue to evaluate Etcamah's potential in different patient populations and treatment settings. The failed trial is a setback rather than an end to the drug's development, as AstraZeneca continues to study camizestrant in other breast cancer settings, including earlier-stage disease. The results underline an important point in cancer treatment: a medicine can work for one specific group of patients or stage of disease but fail to provide a significant benefit when tested in another setting. This setback also comes after another similar drug combination from Roche failed to significantly delay disease progression in a late-stage study earlier this year, highlighting the difficulty of improving treatment outcomes in hormone receptor-positive, HER2-negative breast cancer despite advances in targeted therapies.
